The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy by Tsim, Selina et al.
T
c
p
S
a
b
c
d
e
a
A
R
A
K
C
D
T
M
L
1
k
m
C
Q
h
0
nLung Cancer 103 (2017) 38–43
Contents lists available at ScienceDirect
Lung  Cancer
jou rna l h om epa ge: www.elsev ier .com/ locate / lungcan
he  diagnostic  performance  of  routinely  acquired  and  reported
omputed  tomography  imaging  in  patients  presenting  with  suspected
leural  malignancy
elina  Tsima,b, David  B.  Stoboc, Laura  Alexanderd,  Caroline  Kellyd, Kevin  G.  Blytha,e,∗
Pleural Disease Unit, Queen Elizabeth University Hospital, Glasgow, UK
Institute of Cancer Sciences, University of Glasgow, UK
Department of Radiology, Queen Elizabeth University Hospital, Glasgow, UK
CRUK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, UK
Institute of Infection, Immunity and Inﬂammation, University of Glasgow, UK
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 4 October 2016
ccepted 13 November 2016
eywords:
omputed tomography
iagnosis
horacic oncology
esothelioma
ung cancer
a  b  s  t  r  a  c  t
Objectives:  Contrast-enhanced  computed  tomography  (CT)  provides  essential  cross-sectional  imaging
data  in patients  with  suspected  pleural  malignancy  (PM).  The  performance  of  CT in routine  practice  may
be lower  than  in previously  reported  research.  We  assessed  this  relative  to  ‘real-life’  factors  including  use
of early  arterial-phase  contrast  enhancement  (by CT  pulmonary  angiography  (CTPA))  and  non-specialist
radiology  reporting.
Materials and methods:  Routinely  acquired  and reported  CT scans  in  patients  recruited  to  the  DIAPHRAGM
study  (a  prospective,  multi-centre  observational  study  of  mesothelioma  biomarkers)  between  January
2014 and  April  2016  were  retrospectively  reviewed.  CT reports  were  classiﬁed  as  malignant  if they
included  speciﬁc  terms  e.g. “suspicious  of  malignancy”,  “stage  M1a”  and  benign  if others  were  used e.g.
“indeterminate”,  “no cause  identiﬁed”.  All  patients  followed  a standard  diagnostic  algorithm.  The  diag-
nostic performance  of  CT  (overall  and  based  on  the  above  factors)  was  assessed  using  2 × 2  Contingency
Tables.
Results:  30/345  (9%)  eligible  patients  were  excluded  (non-contrast  (n  = 13)  or non-contiguous  CT  (n =  4),
incomplete  follow-up  (n  = 13)).  195/315  (62%)  patients  studied  had  PM;  90%  were  cyto-histologically
conﬁrmed.  172/315  (55%)  presented  as an  acute  admission,  of  whom  31/172  (18%)  had  CTPA. Overall,
CT  sensitivity  was 58%  (95%  CI 51–65%);  speciﬁcity  was  80%  (95%  CI 72–87%).  Sensitivity  of CTPA  (per-
formed  in  31/315  (10%))  was  lower  (27%  (95%  CI 9–53%))  than  venous-phase  CT  (61% (95%  CI  53–68%)
p  =  0.0056).  Sensitivity  of specialist  thoracic  radiologist  reporting  was  higher  (68% (95%  CI 55–79%))  than
non-specialist  reporting  (53%  (95%  CI 44–62%)  p =  0.0488).  Speciﬁcity  was  not  signiﬁcantly  different.
Conclusion:  The  diagnostic  performance  of  CT  in routine  clinical  practice  is  insufﬁcient  to  exclude  or
conﬁrm  PM.  A benign  CT report  should  not  dissuade  pleural  sampling  where  the presence  of primary  or
secondary  pleural  malignancy  would  alter  management.  Sensitivity  is  lower  with  non-thoracic  radiology
reporting  and  particularly  low  using  CTPA.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Contrast-enhanced Computed Tomography (CT) remains the
ey radiological investigation in patients with suspected pleural
alignancy (PM). [1] Morphological features of PM identiﬁable on
T include pleural thickening >1 cm,  nodular or mediastinal pleu-
∗ Corresponding author at: Department of Respiratory Medicine, Ofﬁce Block,
ueen Elizabeth University Hospital, Glasgow, G51 4TF, UK.
E-mail address: kevin.blyth@ggc.scot.nhs.uk (K.G. Blyth).
ttp://dx.doi.org/10.1016/j.lungcan.2016.11.010
169-5002/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ral thickening, inter-lobar ﬁssural nodularity and inﬁltration of the
chest wall or diaphragm. [2,3] Reports regarding the performance
of CT in this setting show considerable heterogeneity. Previous
prospective studies utilising research study-speciﬁc reporting in
small populations have reported sensitivities of 84–96% and speci-
ﬁcities of 80–100% for PM [4,5] However, a recent retrospective
review of the diagnostic performance of CT in 370 patients referred
for Local Anaesthetic Thoracoscopy (LAT) found lower sensitiv-
ity (68%) and speciﬁcity (78%). [6] In the population studied this
translated into a negative predictive value (NPV) of only 65%, imply-
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
Cance
i
a
h
a
o
w
a
s
t
c
p
t
t
p
2
t
F
M
o
MS. Tsim et al. / Lung 
ng that approximately one third of patients with PM may  have
 benign CT report in routine practice. However, this study may
ave selected a particularly difﬁcult to diagnose population since
ll cases had non-diagnostic or negative pleural aspiration cytol-
gy, by deﬁnition. We  performed a retrospective cohort study in
hich the primary aim was to reassess the performance of routinely
cquired and reported CT in a lessselected population We  retro-
pectively reviewed CT reports in consecutive patients recruited
o the DIAPHRAGM study (ISRCTN10079972). This is a multi-
entre observational study of mesothelioma biomarkers, recruiting
atients at ﬁrst presentation of suspected pleural malignancy. In
his study, patients are generally recruited before, or at diagnos-
ic pleural aspiration, in an ‘intention-to-diagnose’ setting. Most
atients with suspected PM are likely to be eligible (see Section
.1) and CT scans are undertaken as part of routine care. These are
herefore subject to the variations in CT acquisition and radiology
ig. 1. Summary of the diagnostic algorithm following by all subjects recruited to the D
esothelioma) study, including the 315 patients reported here. DIAPHRAGM is a prospec
f  Malignant Pleural Mesothelioma (MPM). DIAPHRAGM incorporates a Magnetic Reson
PM  tumour volume.r 103 (2017) 38–43 39
reporting that exist in clinical practice, including the use of arterial
phase contrast CT (as CTPA) and non-specialist thoracic radiology
reporting. Importantly, the DIAPHRAGM study incorporates robust
diagnostic assessment of all cases, including access to LAT, where
indicated, and mandatory follow-up of benign cases.
2. Materials and methods
2.1. Study population
CT reports were reviewed retrospectively for consecutive
patients recruited prospectively to DIAPHRAGM at 4 centres in the
West of Scotland (Southern General Hospital (now Queen Elizabeth
University Hospital), Glasgow Royal Inﬁrmary, Victoria Inﬁrmary
and Gartnavel General Hospital) between January 2014 and April
2016. The inclusion criteria were suspected pleural malignancy
IAPHRAGM (Diagnostic and Prognostic Biomarkers in the Rational Assessment of
tive, multi-centre observational study assessing novel potential blood biomarkers
ance Imaging (MRI) sub-study allowing correlation between biomarker level and
4 Cancer 103 (2017) 38–43
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deﬁned by a unilateral pleural effusion or pleural mass lesion),
ufﬁcient ﬁtness for at least a pleural aspiration and informed writ-
en consent. The exclusion criteria were an inter-costal chest drain
n-situ, or one within the preceding 3 months.
.2. CT analyses
All CT scans were reported as part of routine clinical activity and
nderwent no study-speciﬁc reporting. Each report was reviewed
y a respiratory physician (ST) who classiﬁed these as malignant
r benign based on speciﬁc terms in the report. Malignant reports
ncluded terms that increased the level of pre-CT clinical suspicion
egarding PM,  speciﬁcally, “suspicious of malignancy”, “probable
alignant effusion”, “disseminated malignancy”, “suggestive of
alignancy”, “stage M1a” or “suggest sampling of effusion for cytol-
gy”. CT reports without terms that increased the level of pre-CT
linical suspicion were classiﬁed as benign. Speciﬁc terms that pos-
tively identiﬁed benign reports were “indeterminate”, “no cause
dentiﬁed”, “no evidence of malignancy”, “differential diagnosis
s wide”, “appearances not obviously malignant” or if alternative
athology was suggested as the likely diagnosis, e.g. tuberculous
leurisy. Thoracic radiologists were deﬁned as radiologists with a
rimary subspecialty interest in chest imaging, including involve-
ent in thoracic oncology multidisciplinary teams. The phase of CT
ontrast enhancement was recorded as CTPA (pulmonary arterial
hase) or non-CTPA (venous phase).
.3. Diagnostic methods
All patients were subject to robust diagnostic assessment based
n a pre-speciﬁed algorithm (see Fig. 1). PM was cytologically or
istologically conﬁrmed where possible. Where not possible PM
as diagnosed by MDT  consensus and demonstration of progres-
ion on follow-up imaging. Patients with benign cytology (+/−
istology if pursued) and evidence of resolution or lack of progres-
ion of pleural disease after a minimum of 6 months of follow-up
ere classiﬁed as benign. Patients with less than 6 months of clin-
cal follow-up were excluded from analyses.
.4. Statistical analysis
Data are presented as mean (±standard deviation (SD)) or
edian (±Interquartile Range (IQR)) depending on the distribu-
ion of the data. CT classiﬁcation (malignant or benign) and the ﬁnal
leural diagnosis (malignant or benign) were compared using 2 × 2
ontingency Tables, generating sensitivity, speciﬁcity and associ-
ted 95% conﬁdence intervals (CI). Negative and positive predictive
alues (NPV and PPV) were calculated using standard deﬁnitions.
ensitivity and speciﬁcity of CTPA vs. non-CTPA and specialist vs.
on-specialist radiology reporting were compared using the Chi-
quared test. Analyses were performed using Graphpad Prism v6.0
San Diego, USA)) and R v2.1.2 (Lucent Technologies, New Jersey,
SA) by ST and CK (Senior Biostatistician, CRUK Glasgow Clinical
rials Unit).
. Results
.1. Study population
The identiﬁcation, exclusion and selection of patients is sum-
arised in Fig. 2. 65% (204/315) of the patients were male, 39%123/315) were asbestos-exposed. 73% (231/315) were current or
x-smokers, 28% (89/315) had a known prior or current non-pleural
alignancy. Median age was 74 (65–79) years. 172/315 (55%) pre-
ented as an acute admission to hospital.Fig. 2. Flow chart of patients identiﬁed, excluded and recruited to the current study.
CT;  Computed Tomography, HRCT; High Resolution CT.
3.2. CT acquisition
CT scans were acquired on a variety of machines (GE Medical
Systems BrightSpeed, LightSpeed or Optima 660; Toshiba Aquil-
ion; Siemens Sensation 4; Philips Brilliance 64). 10% (31/315) of CT
scans were CTPAs, with image acquisition using bolus tracking in
the pulmonary arterial phase. All CTPAs were performed in patients
admitted as an emergency to hospital. 31 of the 172 patients (18%)
who presented as an acute admission had their CT performed as
a CTPA. All other patients had venous phase imaging, with images
acquired 60–70 s post-contrast.
3.3. CT results
CT scans were classiﬁed as malignant in 43.5% (137/315) and
benign in 56.5% (178/315). 77 radiologists were involved in report-
ing; 22% (17/77) were thoracic radiologists. 37% (115/315) of scans
were reported by a thoracic radiologist, of which 50% (57/115)
were classiﬁed as malignant. 40% (80/200) of scans reported by
non-thoracic radiologists were reported as malignant.
3.4. Pleural diagnoses
These data are summarised in Table 1. The prevalence of PM
was 62% (195/315). 90% (176/195) of PMs  were cyto-histologically
conﬁrmed. The median follow-up for all cases was 334 (212–577)
days. Median follow-up for cases of Benign Asbestos Pleural Effu-
sion (BAPE) was  298 (107–840) days.
3.5. Diagnostic performance of CT
The diagnostic performance characteristics of CT for PM are
summarised in Table 2, the 2 × 2 Contingency tables used to gen-
erate these data are summarised in Table 3. The sensitivity of CTPA
(27% (95% CI 9–53%)) was  signiﬁcantly lower than CT acquired in
the venous phase of contrast enhancement (61% (95% CI 53–68%),
S. Tsim et al. / Lung Cancer 103 (2017) 38–43 41
Table  1
Summary of Pleural Diagnoses in 315 patients subject to routinely acquired and reported Computed Tomography imaging for suspected Pleural Malignancy.
Pleural Malignancy (n = 195, 62%) Benign Disease (n = 120, 38%)
Mesothelioma (n = 59, 19%) BAPE (n = 23, 7%)
Secondary Malignancies (n = 137, 43%) Pleural Infection (n = 12, 4%)
Lung Cancer (n = 74, 23%) Reactive assoc. with Lung Cancer (n = 12, 4%)
Breast Cancer (n = 14, 4%) Cardiac or Liver Transudates (n = 23, 7%)
Renal Cancer (n = 8, 3%) Fibrothorax (n = 5, 2%)
Haematological Cancer (n = 7, 2%) Tuberculous Pleuritis (n = 7, 2%,)
Gynaecological Cancer (n = 8, 3%) Inﬂammatory Pleuritis (n = 9, 3%)
Other deﬁned malignancy (n = 17, 5%) Pulmonary Thromboembolism (n = 1, 0.3%)
Unknown Primary (n = 9, 3%) Drug-related (n = 1, 0.3%)
Chylothorax (n = 1, 0.3%)
Post-cardiac surgery (n = 1, 0.3%)
Pancreatitis (n = 1, 0.3%)
Reactive secondary to Fibroids (n = 1, 0.3%)
Post-lobectomy (n = 2, 0.6%)
No speciﬁc diagnosis madea (n = 21, 6.6%)
B
p
C
t
T
n
4
a
b
c
r
t
4
f
7
a
P
r
r
m
T
T
b
CAPE; Benign Asbestos-related Pleural Effusion.
a with reassuring clinical follow-up of at least 6 months.
 = 0.0056). The speciﬁcity of CTPA appeared lower (69% (95%
I 38–90%) than venous phase CT (82% (95% CI 73–88%)) but
his difference did not reach statistical signiﬁcance (p = 0.2712).
he sensitivity of thoracic radiology reporting was  higher than
on-thoracic reporting (68% (95% CI 55–79%) versus 53% (95% CI
4–62%), p = 0.0488). The speciﬁcity of thoracic radiology reporting
ppeared lower (75% (95% CI 61–86%) versus 84% (95% CI 73–92%)),
ut this difference did not reach statistical signiﬁcance (p = 0.2184).
108/315 (34%) patients had CT acquired using venous-phase
ontrast enhancement and had subsequent thoracic radiology
eporting. These ‘optimal’ conditions were associated with a sensi-
ivity of 69% (95% CI 56–80%) and speciﬁcity of 73% (95% CI 58–85%).
. Discussion
The overall sensitivity and speciﬁcity of contrast-enhanced CT
or PM in this study were 58% (95% CI 51–65%) and 80% (95% CI
2–87%), respectively, resulting in a PPV of 83% (95% CI 75–89%)
nd a NPV of 54% (95% CI 46–61%). Almost half of the patients with
M had a benign CT report. This strongly suggests that a benign CT
eport should not dissuade clinicians from pursuing invasive pleu-
al investigations if the presence of primary or secondary pleural
alignancy would alter management. The sensitivity (27% (95% CI
able 2
he diagnostic performance of routinely acquired and reported Computed Tomography (C
ased on relevant image acquistion and reporting factors.
Sensitivity
(95% CI)
All patients (n = 315) 58%
(51–65%)
Image Acqusition
Venous-phase contrast CT (n = 284) 61%
(53–68%)
CTPA (arterial-phase contrast) (n = 31) 27%*
(9–53%)
Image Reporting
Specialist Thoracic Radiologist (n = 115) 68%
(55–79%)
Non-specialist Thoracic Radiologist (n = 200) 53%**
(44–62%)
Optimal Acquistion and Reporting
Venous-phase contrast CT reported by a thoracic
radiologist (n = 108)
69%
(56–80%)
I; Conﬁdence Interval, PPV; Positive Predictive Value, NPV; Negative Predictive Value, C
* p < 0.01 (CTPA vs. venous-phase CT).
** p < 0.05 (thoracic vs. non-thoracic radiology reporting).9–53%)) and NPV (40% (20%–63%)) of arterial phase CT (as CTPA)
was particularly low. Even allowing for the small numbers and wide
conﬁdence intervals around these data, the use of CTPA images to
diagnose benign pleural disease must seriously be questioned.
The performance of CT reported in the current study is signif-
icantly inferior to results from some earlier studies. For example,
Hierholzer et al. reported sensitivity of 93% and speciﬁcity of 87% in
42 patients [5], while Metintas reported up to 70% sensitivity and
96% speciﬁcity in 215 patients [3]. These differences may  reﬂect
the involvement of specialist thoracic radiologists in these research
projects. We  certainly found that thoracic radiology reporting was
associated with greater sensitivity, albeit at the potential cost of
a reduction in speciﬁcity (which did not reach statistical signiﬁ-
cance). The results of the current study are concordant with those
of similarly sized (n = 370) study reported by Hallifax et al. in which
CT performance was  retrospectively assessed in patients referred
for local anaesthetic thoracoscopy (LAT) for suspected PM (sensi-
tivity 68% (95% CI 62–75%), speciﬁcity 78% (95% CI 72–84%), NPV
65% (95% CI 58–72%), PPV 80% (95% CI 75–86%). [6] This study used
similar report terms to classify patients into malignant and benign
CT cohorts but described a more selected population than our own,
since only those referred for LAT were eligible. LAT is indicated
when initial pleural diagnostics are non-speciﬁc, the suspicion of
T) imaging in 315 patients with suspected Pleural Malignancy. Results are stratiﬁed
Speciﬁcity
(95% CI)
PPV (95%
CI)
NPV (95%
CI)
80%
(72–87%)
83%
(75–89%)
54%
(46–61%)
82%
(73–88%)
85%
(77–90%)
56%
(48–64%)
69%
(38–90%)
55%
(21–86%)
40%
(20–63%)
75%
(61–86%)
78%
(66–88%)
63%
(50–76%)
84%
(73–92%)
86%
(76–92%)
50%
(40–59%)
73%
(58–85%)
78%
(65–88%)
63%
(48–76%)
TPA; CT pulmonary angiography.
42 S. Tsim et al. / Lung Cance
Table 3
2 × 2 Contingency Tables describing results of routinely acquired and reported
Computed Tomography (CT) imaging and diagnostic assessment according to a
standardised algorithm in 315 patients with suspected Pleural Malignancy.
Final Pleural Diagnosis
Malignant Benign
All patients (n = 315)
CT report Malignant 114 23
Benign 81 97
Venous-phase contrast CT (n = 284)
CT  report Malignant 109 19
Benign 68 88
Arterial-phase contrast CT (CTPA) (n = 31)
CT  report Malignant 5 4
Benign 13 9
Thoracic Radiologist Reporting (n = 115)
CT report Malignant 45 12
Benign 21 37
Non-thoracic Radiologist Reporting (n = 200)
CT report Malignant 69 11
Benign 60 60
Optimal CT (Venous-phase and Thoracic Radiologist Reporting) (n = 108)
CT  report Malignant 44 12
Benign 19 33
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alignancy is high and the patient is ﬁt for the procedure. The
opulation studied in this previous study could therefore be con-
idered to be a more difﬁcult to diagnose cohort to the current study
ohort, in which 89/315 (28%) patients had diagnostic pleural cytol-
gy and only 35% (111/315) required a subsequent pleural biopsy.
 conﬁdent clinical diagnosis of benign disease was achieved in
he remaining 37% (115/315) without the need for further sam-
ling. The incidence of Mesothelioma was also signiﬁcantly lower
n the current study (19%) than in the earlier Hallifax study (54.5%)
eﬂecting the earlier recruitment required in DIAPHRAGM. These
actors all deﬁne the current study cohort as an easier to diagnose
opulation than the Hallifax study [6] and one that is more rep-
esentative of the intention-to-diagnose population in which CT is
outinely used in patients with suspected PM.  Despite this and the
se of similar methods, CT sensitivity and NPV were both lower in
he current study (58% (95% CI 51–65%) and 54% (95% CI 46–61%))
han in Hallifax et al. with similar PM prevalence (62% herein vs.
7% [6]) and speciﬁcity.
Possible explanations for this may  include differences in the
ype of CT images acquired and the reporting performed. The cur-
ent study was recruited across 22 UK and Irish hospitals (including
 mixture of academic and clinical centres to ensure generalizabil-
ty of DIAPHRAGM’s results). This may  have differed to recruitment
rom two tertiary pleural disease units (Oxford and Preston) in
he Hallifax study. Our design may  have led to greater use of
non-optimised’ CT including more use of CTPA and non-thoracic
adiology reporting, although these factors are not reported by
allifax et al. and cannot be directly compared.
We found that the sensitivity of CTPA (27% (95% CI 9–53%)) for
M was signiﬁcantly inferior to that of venous-phase CT (sensi-
ivity 61% (95% CI 53–68%), p = 0.0056). The NPV of CTPA for PM
as only 40% (95% CI 20–63%). To our knowledge, this is the ﬁrst
eport to directly compare the diagnostic performance of arte-
ial phase CTPA to later-phase enhanced CT in the assessment of
M. In a previous prospective study Hooper et al. performed CTPA
nd late arterial phase CT (optimised for pleural imaging) in 141
atients with suspected PM.  However the primary objective of this
tudy was to assess the incidence of pulmonary emboli [7] and
he diagnostic performance of CTPA for PM was not reported. In ar 103 (2017) 38–43
small randomised study, Raj et al. previously demonstrated better
enhancement of the pleura utilising delayed phase (at 60–90 s post-
contrast) CT acquisition [8], Therefore venous-phase CT should be
requested in all patients with suspected PM, and this may  have
been used more frequently in the Hallifax study. Our study clearly
demonstrates that this approach is frequently not taken in a more
generalizable population and may  be even less frequently used than
reported here, since our centres did have a stated interest in pleu-
ral disease and were recruiting to DIAPHRAGM. A major reason for
this is the frequency of emergency presentation with suspected PM.
Previous Mesothelioma series have reported up to 50% of cases pre-
senting in this manner [9,10] and this is corroborated here, with 172
of the 315 patients (55%) presenting as an emergency to an acute
medical receiving unit. 31/172 (almost 1 in 5) of these case had CT
performed as a CTPA to exclude concomitant pulmonary thrombo-
embolism, presumably driven by non-speciﬁcally high D-Dimer
results, although this was  not speciﬁcally assessed here. Despite
the small numbers and resulting wide conﬁdence intervals around
our results (particularly a sensitivity of 27% (95% CI 9–53%)) the use
of CTPA for pleural diagnostics should be seriously questioned and
repeat imaging with optimised ‘pleural’ contrast enhancement in
the venous phase should be considered where a positive result will
alter management.
The diagnostic sensitivity of CT was  higher in the current study
when thoracic radiologists were involved in reporting (69% (95% CI
55–79%) vs. 53% (95% CI 44–62%) for non-thoracic radiology report-
ing, p = 0.0488). Optimal imaging conditions (i.e. venous-phase
acquisition and thoracic radiology reporting) were associated with
a sensitivity of 69% (95% CI 56–80%), although the number of
patients imaged under sub-optimal conditions (i.e. CTPA reported
by non-thoracic radiologists) was too small (n = 24) to allow a
meaningful comparison between these extremes. These data sug-
gest that increased specialist radiology reporting may improve
the performance of CT in the routine assessment of patients pre-
senting with PM.  However, a limited workforce with job-plans
already committed to MDT  provision and image-guided biopsy
services make this difﬁcult to deliver. For example, in this study tho-
racic radiologists comprised only 22% of the radiologists involved
and reported only 37% of the scans. As a result, optimal imaging
conditions were only achieved in 108/315 (34%) of the patients
studied. The development of objective imaging biomarkers of PM
may  therefore provide a better long-term method of reducing
inter-observer disagreement in CT reporting, as has previously
been demonstrated in breast cancer [11,12] Novel objective imag-
ing markers of PM are also under development including Pleural
Pointillism [13] and Early Contrast Enhancement [14], both deﬁned
using MRI.
4.1. Study weaknesses and strengths
Although all patients included in this study were recruited
prospectively, the classiﬁcation of each CT report as malignant
or benign was  performed retrospectively. However, pre-speciﬁed
criteria were set in advance as to which terms would constitute
malignant and benign reports and these were used consistently.
The ﬁnal pleural diagnosis end-point used in the study is likely
to be robust given the rigorous prospective assessment required
by the DIAPHRAGM study protocol. This included ready access to
thoracoscopy (and/or image-guided biopsy), a lung and regional
mesothelioma MDT  review (where appropriate) and a specialist
pleural clinic follow-up for all cases. This was reﬂected in a high
cyto-histological conﬁrmation rate of PM (90%). However, the min-was only 6 months. Theoretically, this could result in an underes-
timation of the true Mesothelioma rate since it is normal practice
to follow up patients with Benign Asbestos Pleural Effusion (BAPE,
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[16] Royal College of Radiology, Recommendations for cross-sectional imaging in
cancer management, in: General Techniques for Examinations Discussing CT,
Biopsy and MRI, second edition, 2016 (Accessed 20 September 2016) https://
www.rcr.ac.uk/system/ﬁles/publication/ﬁeld publication ﬁles/
BFCR%2814%292 2 General.pdf.S. Tsim et al. / Lung 
3/315 (7%) of the patients studied) for at least 2 years, because of a
otential false negative pleural biopsy rate of up to 12% in previous
ase series. [15] However, all cases of BAPE were subject to manda-
ory clinical follow-up as per the DIAPHRAGM study protocol (see
ig. 1) and the mean follow-up for the patients diagnosed with BAPE
n this current study was 367 (SD 220) days. Furthermore, it is not
lear whether Mesothelioma in follow-up represents a new diag-
osis at that point or a genuine false negative based on the original
ssessment.
. Conclusions
In clinical practice, CT plays a major role in the assessment of
atients with suspected pleural malignancy. The interpretation of
he CT scan by the referring clinician and the reporting radiolo-
ist frequently directs the patient towards, or away from further
iagnostics, including invasive pleural sampling. This is the sec-
nd study assessing the diagnostic performance of CT for pleural
alignancy in routine clinical practice, and demonstrates signif-
cantly lower sensitivity and speciﬁcity than previously reported
n smaller research studies. Given the NPV reported here (54%
95% CI 46–61%)) it is important to consider invasive (cyto-
ogical ± histological) sampling in patients where proven pleural
alignancy would alter management.
The low sensitivity and NPV of CTPA strongly suggest that this
odality is inadequate for the exclusion of PM.  Either repeat CT
maging with pleural contrast timing, alternative imaging (e.g.
agnetic resonance imaging) or further investigation if there are
ther indicators of pleural malignancy should be considered after
 benign CTPA report. For patients with pleural effusion, revision
f existing guidelines advocating routine imaging of the thorax in
he arterial phase for oncological purposes [16] should be consid-
red. Given the high level of skill required to interpret pleural CT
mages, increased specialty reporting may  immediately improve
he performance of CT in routine clinical practice. In addition, the
evelopment of more objective imaging biomarkers of PM may
esult in better performance by reducing operator dependence.
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